Achieve Life Sciences (ACHV) Expected to Announce Earnings on Tuesday

Achieve Life Sciences (NASDAQ:ACHV - Get Free Report) is projected to release its Q4 2024 earnings data before the market opens on Tuesday, March 11th. Analysts expect Achieve Life Sciences to post earnings of ($0.30) per share for the quarter. Parties interested in registering for the company's conference call can do so using this link.

Achieve Life Sciences (NASDAQ:ACHV - Get Free Report) last issued its quarterly earnings data on Tuesday, March 11th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.06). On average, analysts expect Achieve Life Sciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Achieve Life Sciences Stock Performance

Shares of NASDAQ:ACHV traded up $0.00 on Thursday, reaching $2.65. 184,764 shares of the company's stock were exchanged, compared to its average volume of 255,455. Achieve Life Sciences has a twelve month low of $2.59 and a twelve month high of $5.59. The company has a fifty day moving average of $3.20 and a 200-day moving average of $4.04. The company has a market capitalization of $91.27 million, a price-to-earnings ratio of -2.35 and a beta of 1.67. The company has a current ratio of 6.78, a quick ratio of 6.78 and a debt-to-equity ratio of 0.31.

Remove Ads

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on ACHV. RODMAN&RENSHAW raised Achieve Life Sciences to a "strong-buy" rating in a report on Thursday, November 14th. Rodman & Renshaw began coverage on Achieve Life Sciences in a research note on Thursday, November 14th. They issued a "buy" rating and a $12.00 price target for the company. Three analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Buy" and an average target price of $15.75.

About Achieve Life Sciences

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.